Aetna · Eohilia · US health-plan appeal rights

Eohilia denied due to quantity / dose limits by Aetna?

Q: How long do I have to appeal a Aetna Eohilia denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Quantity-limit denials usually flip when the appeal documents the clinically appropriate dose for the patient's weight, kidney function, or escalation schedule, citing the FDA label or specialty-society guideline.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-10

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Aetna typically requires

Aetna's specific coverage criteria for eohilia are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: Aetna CPB on Eohilia (Budesonide Oral Suspension)

The Aetna angle on Eohilia

## Why Aetna Applies Quantity Limits to Eohilia

Eohilia (budesonide oral suspension) for eosinophilic esophagitis (EoE) is subject to quantity-limit controls under Aetna's utilization-management program. These limits specify the maximum supply (number of units, bottles, or days' supply) the plan will cover within a given period. A quantity-limit denial arises when the prescribed quantity — or the cumulative quantity dispensed — exceeds Aetna's published limit for the coverage period.

Quantity limits do not mean the plan refuses to cover the drug entirely. They mean you need a separate authorization to obtain more than the plan's default quantity, which requires demonstrating medical necessity for the higher amount.

## Your Federal Appeal Rights

Internal appeal: ERISA §503 and ACA §2719 require plans to provide a full-and-fair review of any adverse benefit determination, including quantity-limit denials. You have the right to know the exact quantity criteria Aetna applied.
External review (ACA §2719): If the internal appeal is denied, you may request independent external review from an accredited IRO. External reviewers evaluate whether quantity restrictions are consistent with the FDA-approved prescribing information and generally accepted standards of care for EoE.
Expedited review: If the delay in receiving the prescribed quantity poses a serious health risk, request expedited review — plans must respond within 72 hours.
Timeline: External review requests are typically accepted within approximately four months of the final internal denial. Confirm the exact deadline on your denial letter.

## The Concrete Appeal Process

1. Request Aetna's published quantity-limit criteria for Eohilia in writing. 2. Compare the prescribed quantity against the FDA-approved prescribing label — if the prescription is within label, note this explicitly. 3. Have your prescriber document the clinical basis for the prescribed quantity (e.g., treatment phase, duration of therapy recommended by the specialist, response to treatment requiring continuation). 4. Submit a written internal appeal with the documentation below, arguing the quantity is medically necessary and consistent with the FDA label and applicable EoE guidelines. 5. If denied on internal review, file for external review.

## Documentation to Gather

Current treatment plan: The prescriber's documented treatment plan specifying the recommended course of therapy, why the prescribed quantity aligns with standard-of-care treatment duration, and any specialist society guidance on treatment length (cite the organization, not specific numbers).
Clinical response records: Chart notes documenting symptom changes, endoscopic findings over time, and the basis for continuing or extending the treatment course.
FDA prescribing label: A copy or reference to the approved prescribing information confirming that the prescribed quantity is within the labeled dosing guidance.
Prescriber medical-necessity letter: A signed letter from the treating specialist explaining why the specific quantity prescribed is necessary for this patient's clinical situation.

## Criteria-Mapping Strategy

The pivotal question in a quantity-limit appeal is whether the FDA-approved label — and the treating specialist's clinical judgment applied to this patient — supports the quantity prescribed. Build the appeal around two anchors: (1) the relevant section of the FDA prescribing information on treatment duration or administration schedule, and (2) the chart documentation of your prescriber's clinical rationale. When these two sources align, the case for exceeding a default quantity limit is strong.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Aetna appeals

Other denial reasons for Aetna Eohilia

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-10. Editorial standards: denialhelp.com/authors.